LivaNova PLC (NASDAQ:LIVN) Shares Bought by Northern Trust Corp

Northern Trust Corp lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 11.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 703,019 shares of the company's stock after buying an additional 70,630 shares during the period. Northern Trust Corp owned approximately 1.29% of LivaNova worth $32,557,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after purchasing an additional 219 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of LivaNova by 1.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company's stock valued at $780,000 after purchasing an additional 289 shares during the period. Xponance Inc. boosted its holdings in LivaNova by 6.1% during the fourth quarter. Xponance Inc. now owns 7,762 shares of the company's stock worth $359,000 after buying an additional 445 shares in the last quarter. Mariner LLC grew its position in LivaNova by 8.4% during the fourth quarter. Mariner LLC now owns 5,741 shares of the company's stock valued at $266,000 after buying an additional 446 shares during the period. Finally, Invesco Ltd. increased its holdings in LivaNova by 0.6% in the fourth quarter. Invesco Ltd. now owns 111,374 shares of the company's stock valued at $5,158,000 after buying an additional 667 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Trading Down 1.2%

NASDAQ:LIVN traded down $0.51 during trading hours on Wednesday, hitting $43.55. The company had a trading volume of 773,346 shares, compared to its average volume of 642,646. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $63.57. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The company has a 50-day moving average of $38.06 and a 200 day moving average of $45.03. The company has a market cap of $2.37 billion, a P/E ratio of 103.69 and a beta of 0.84.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on LIVN shares. Robert W. Baird lifted their price target on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wolfe Research cut shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Stifel Nicolaus cut their target price on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. The Goldman Sachs Group decreased their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Finally, StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $59.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.